Back to results
US 9,435,809 B2Granted
Method of treating and reducing the risk of acute myelogenous leukemia
AssigneeMemorial Sloan Kettering Cancer Center
InventorsStephen D. Nimer, Lan Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments.
Claims17
A method of identifying agents for treating or reducing risk for acute myelogenous leukemia comprising:
- providing a system comprising at least AML1-ETO and p300, in which AML1-ETO acetylation level is determinable;
- contacting the system with a test agent;
- determining AML1-ETO acetylation level when the test agent is present;
- comparing the determined AML1-ETO acetylation level with a reference AML1-ETO acetylation level so that any difference between the reference level and the determined level is detected;
- and
- characterizing the test agent's usefulness in treating or reducing risk for acute myelogenous leukemia based on the detected difference.
3 more elements
Dependencies are inferred from the claim text.